James C. Yao, MD (Medical Oncology)
The University of Texas M.D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Comments: by Dr. Yao
We are leading the development of RAD001 trials. We have completed accrual to the MDA single institution trial. There are three large multi-institution Novartis sponsored trials.
1. Phase II study in islet cell carcinoma after chemotherapy (either progression while on chemo or progression anytime after completion of 3 courses of chemo). This study is open.
2. Phase III study in carcinoid to open probably in January
3. Phase III study in islet cell (prior chemo not required) to open later in 2007
We have sent patient (sic) to Rotterdam for LU177 octreotate before as well.
Patient needs to be seen for screening to make sure that they are eligible. There are a number of tests required by the Rotterdam group for the referral process. Dr.Yao’s specialty is in clinical trials.